Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akari Therapeutics PLC

1.08
+0.172118.96%
Post-market: 0.9801-0.0999-9.25%19:42 EDT
Volume:10.18K
Turnover:9.72K
Market Cap:26.74M
PE:-0.44
High:1.08
Open:0.9550
Low:0.9318
Close:0.9079
Loading ...

Company Profile

Company Name:
Akari Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
11
Office Location:
22 Boston Wharf Road,Floor 7,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
929 274 7553
Introduction:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Directors

Name
Position
Clive Richardson
Director,Chief Executive Officer and Chief Operating Officer
Ray Prudo
Director,Executive Chairman of the Board
David Byrne
Director
Donald Williams
Director
James Hill
Director
Michael Grissinger
Director
Peter Feldschreiber
Director
Stuart Ungar
Director

Shareholders

Name
Position
Clive Richardson
Director,Chief Executive Officer and Chief Operating Officer
Ray Prudo
Director,Executive Chairman of the Board